國家衛生研究院 NHRI:Item 3990099045/15099
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 852142      在线人数 : 1375
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/15099


    题名: Glucagon-like peptide-1 receptor agonist use in patients with liver cirrhosis and type 2 diabetes
    作者: Yen, FS;Hou, MC;CC Wei, J;Shih, YH;Hsu, CY;Hsu, CC;Hwu, CM
    贡献者: Institute of Population Health Sciences;National Center for Geriatrics and Welfare Research
    摘要: BACKGROUND & AIMS: Liver cirrhosis is often associated with type 2 diabetes (T2D), but research on treatment of T2D in cirrhotic patients is scarce. We investigated the long-term outcomes of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with T2D and cirrhosis. METHODS: Using propensity-score matching, we selected 467 matched pairs of GLP-1 RA users and nonusers from the National Health Insurance Research Database of Taiwan from January 1, 2008, to December 31, 2019. Multivariable-adjusted Cox proportional hazards models were used to compare the outcomes between GLP-1 RA users and nonusers. RESULTS: The mean follow-up time was 3.28 and 3.06 years for GLP-1 RA users and nonusers, respectively. The rates of death were 27.46 and 55.90 per 1000 person-years for GLP-1 RA users and nonusers, respectively. The multivariable-adjusted models showed that GLP-1 RA users had lower risks of mortality (aHR 0.47, 95%CI 0.32-0.69), cardiovascular events (aHR 0.6, 95%CI 0.41-0.87), decompensated cirrhosis (aHR 0.7, 95%CI 0.49-0.99), hepatic encephalopathy (aHR 0.59, 95%CI 0.36-0.97), and liver failure (aHR 0.54, 95%CI 0.34-0.85) than nonusers. A longer cumulative duration of GLP-1 RA use had a lower risk of these outcomes than GLP-1 RA no-use. CONCLUSIONS: This population-based cohort study showed that GLP-1 RA users exhibited a significantly lower risk of death, cardiovascular events, decompensated cirrhosis, hepatic encephalopathy, and liver failure in patients with T2D and compensated liver cirrhosis. Additional studies are needed to confirm our results.
    日期: 2024-06
    關聯: Clinical Gastroenterology and Hepatology. 2024 Jun;22(6):1255-1264.e18.
    Link to: http://dx.doi.org/10.1016/j.cgh.2023.06.004
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1542-3565&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:001246279400001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85165633010
    显示于类别:[許志成] 期刊論文
    [許志成] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    PUB37331413.pdf1771KbAdobe PDF130检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈